Cytokinetics Shares Rise 4% on Bristol Update

Cytokinetics shares jumped 4% on Thursday, outperforming the Nasdaq Biotechnology Index’s 1% gain after Bristol’s ACACIA trial update.
Bank of America analysts note Bristol’s renewed commitment to non‑obstructive hypertrophic cardiomyopathy, but remain uncertain about Cytokinetics’ success probability.
BofA consulted ~six key opinion leaders, citing skepticism on mechanistic rationale and unclear optimal patient population for Cytokinetics’ drug.
Analysts view Bristol as a major competitor, with most KOLs seeing its drug and Cytokinetics’ as more similar than different.